Spasticity Drugs Market Report Scope & Overview:

The Spasticity Drugs Market was valued at USD 1.46 Billion in 2025 and is expected to reach USD 3.09 Billion by 2035, growing at a CAGR of 7.78% from 2026-2035.

The Spasticity Drugs Market will see traction due to the growing burden of neurological disorders such as stroke, multiple sclerosis, cerebral palsy, and spinal cord injury, along with wider use of botulinum toxin injections and intrathecal baclofen therapy in rehabilitation settings. Drug therapy has moved from broad systemic muscle relaxants toward targeted, muscle-specific treatment guided by ultrasound and electrical stimulation. New patient-friendly formulations such as oral granules and ready-to-use suspensions are improving adherence among patients with swallowing difficulties. Supportive reimbursement for neurotoxin injections in developed markets and expanding neurology access in emerging economies continue to widen the treated patient pool.

In May 2026, Ipsen presented results from DIRECTION, the first prospective head-to-head Phase IV trial of Dysport versus Botox in 464 adults with upper limb spasticity across 72 sites. The trial met its primary and secondary endpoints, showing a non-inferior safety profile and longer duration of response for Dysport, strengthening its position with rehabilitation specialists.

Spasticity Drugs Market Trends:

• Rising use of ultrasound-guided botulinum toxin injections for precise, muscle-specific dosing.

• Growing launch of liquid and granule baclofen formulations for patients with swallowing difficulties.

• Increasing adoption of next-generation programmable intrathecal pumps for severe spasticity.

• Expanding pediatric label extensions for neurotoxins in cerebral palsy-related spasticity.

• Growing head-to-head and real-world evidence generation to differentiate neurotoxin brands.

• Rising investment in gene therapies and novel molecules targeting hereditary spastic paraplegia.

U.S. Spasticity Drugs Market Outlook:

The U.S. Spasticity Drugs Market was valued at USD 0.52 Billion in 2025 and is expected to reach USD 1.04 Billion by 2035, growing at a CAGR of 7.18% from 2026-2035.

The U.S. spasticity drug market is expanding due to the sizeable patient pool of stroke, multiple sclerosis and spinal cord injury sufferers, with close to one million people in America thought to have multiple sclerosis. Good coverage of botulinum toxin injection and intrathecal baclofen treatment by Medicare and other insurance companies ensures stable adoption of these therapies. The United States is at the forefront when it comes to neurotoxin manufacturers, specialty drug makers and generic baclofen and tizanidine makers. 505(b)(2) approval process by the FDA has helped in the development of oral suspensions and granules, while a large base of physiatrists keeps injectable drug demand robust.

In October 2023, Medtronic received FDA approval for its SynchroMed III intrathecal drug delivery system for severe spasticity, chronic pain, and cancer pain. The upgraded pump features a refill-only physician workflow, firmware that can be updated after implant, and enhanced cybersecurity, supporting broader use of Lioresal Intrathecal and Gablofen baclofen therapy across U.S. centers.

Spasticity Drugs Market Segment Analysis:

• By Drug Class, the GABA Agonists segment dominated the Spasticity Drugs Market with approximately 38.46% share in 2025, while the Botulinum Toxins segment is the fastest growing with a CAGR of approximately 8.94%.

• By Indication, the Cerebral Palsy segment dominated the Spasticity Drugs Market with approximately 34.72% share in 2025, while the Multiple Sclerosis segment is the fastest growing with a CAGR of approximately 8.61%.

• By Route of Administration, the Oral segment dominated the Spasticity Drugs Market with approximately 51.37% share in 2025, while the Intrathecal segment is the fastest growing with a CAGR of approximately 8.83%.

• By Patient Age Group, the Adults segment dominated the Spasticity Drugs Market with approximately 73.85% share in 2025, while the Pediatrics segment is the fastest growing with a CAGR of approximately 8.47%.

• By Distribution Channel, the Hospital Pharmacies segment dominated the Spasticity Drugs Market with approximately 48.92% share in 2025, while the Online Pharmacies segment is the fastest growing with a CAGR of approximately 9.71%.

By Drug Class, GABA Agonists Lead, While Botulinum Toxins Grow Fastest

GABA agonists segment dominated the Spasticity Drugs Market in 2025, as baclofen remains the first-line systemic therapy for spasticity caused by multiple sclerosis and spinal cord injury. Its long clinical track record, low cost as a widely available generic, and availability in tablets, oral suspensions, granules, and intrathecal injections allow physicians to treat patients across all levels of severity. Branded reformulations such as Ozobax, Fleqsuvy, and Lyvispah have extended the class to patients who cannot swallow tablets or rely on feeding tubes. In addition, intrathecal baclofen delivered through implanted pumps generates high per-patient value in severe cases, further reinforcing the segment’s revenue leadership across hospitals and specialty neurology clinics.

Botulinum toxin is among the fastest growing group of drugs due to growing preference for the use of selective injections to treat overactive muscles in a non-drowsy and non-weakening manner unlike the oral drugs. The products include Botox, Dysport, and Xeomin which have been approved for both upper and lower limb spasticities in both adult and pediatric populations. The current injection cycle provides great value when compared to other oral generics. The use of ultrasound guided injections has improved dosing and outcome of the procedure. Future head to head trials, pediatric label extensions and improvement in rehabilitation facilities in Asia-Pacific and Latin America will drive future growth in the market.

By Indication, Cerebral Palsy Leads, While Multiple Sclerosis Grows Fastest

Cerebral palsy segment dominated the Spasticity Drugs Market in 2025, since the spastic form accounts for roughly 80% of all cerebral palsy cases and represents the most common motor disability in childhood. Patients typically require lifelong management that combines oral baclofen, repeated botulinum toxin injection cycles, and intrathecal baclofen for severe generalized spasticity. Early diagnosis programs, multidisciplinary pediatric rehabilitation centers, and growing awareness among parents and caregivers are increasing the number of children receiving drug therapy. Approvals of Botox and Dysport for pediatric upper and lower limb spasticity, along with ongoing trials such as Neurotech International’s NTI164 program, continue to strengthen treatment demand across this indication.

Multiple sclerosis is the fastest-growing indication, as more than 2.8 million people are estimated to live with the disease worldwide, and a large share experience spasticity during the course of the illness. Better diagnosis through MRI, longer survival due to disease-modifying therapies, and the rising number of women diagnosed with the condition are expanding the long-term patient pool. Symptom management guidelines recommend baclofen, tizanidine, gabapentin, and cannabinoid-based options such as nabiximols for MS-related spasticity. New oral liquid formulations approved specifically for multiple sclerosis patients, combined with growing access to specialist MS centers in Asia-Pacific and the Middle East, are expected to drive strong growth in this segment.

By Route of Administration, Oral Leads, While Intrathecal Grows Fastest

Oral leads dominated the Spasticity Drugs Market in 2025, owing to the ease of administration, cost-effectiveness, and widespread availability of drugs like baclofen, tizanidine, dantrolene, diazepam, and gabapentin. Oral medicines still continue to be the first line of treatment for people suffering from spasticity as a whole and for mild to moderate spasticity managed through primary care or neurology outpatient clinics. The presence of a solid base for the production of generic drugs in countries such as India and the US ensures that the prices remain affordable and supplies consistent both in developed and developing economies. Re-formulations of oral liquids and granules have improved adherence among geriatric patients, pediatric population, and dysphagia sufferers post-stroke, thus retaining the dominant position of the oral drugs market segment.

The intrathecal segment is the fastest-growing route of administration, as intrathecal baclofen delivers the drug directly into the spinal fluid and achieves strong symptom control at a fraction of the oral dose. This approach is increasingly used for severe spasticity in cerebral palsy, spinal cord injury, and advanced multiple sclerosis when oral drugs cause excessive side effects. Next-generation programmable pumps such as Medtronic’s SynchroMed III are simplifying refill workflows and improving device reliability for clinicians. Wider availability of Lioresal Intrathecal and Gablofen, better reimbursement for pump implantation, and growing numbers of trained neurosurgery centers are expected to support rapid expansion of intrathecal therapy.

Regional Analysis:

North America Spasticity Drugs Market Insights

North America accounted for approximately 41.62% of the Spasticity Drugs Market in 2025, the largest share among all regions, supported by a high prevalence of stroke, multiple sclerosis, and spinal cord injury and strong reimbursement for neurotoxin and intrathecal therapies. The United States generates most of the regional revenue, backed by the presence of leading companies such as AbbVie, Ipsen, Merz Therapeutics, Medtronic, Amneal, and Azurity Pharmaceuticals. The FDA’s 505(b)(2) pathway has enabled a steady flow of reformulated baclofen products, including oral suspensions and granules, that address unmet needs for patients with swallowing difficulties. A dense network of physiatrists, neurologists, and rehabilitation hospitals also ensures high diagnosis and treatment rates.

Clinical evidence generation remains strongest in the region, with major head-to-head neurotoxin trials and long-term registry studies enrolling patients across U.S. and Canadian sites. Canada contributes a stable share, driven by provincial coverage of botulinum toxin injections and specialist spasticity clinics in academic hospitals. Mexico represents a smaller but expanding market, as private hospital networks increase access to injectable therapies and as rising stroke incidence lifts demand for rehabilitation care. Growing use of telehealth for follow-up visits, expanding home infusion services for intrathecal pump refills, and higher awareness among caregivers are expected to support steady regional growth throughout the forecast period.

Europe Spasticity Drugs Market Insights

Europe is the second-biggest market for spasticity therapy, comprising Germany, UK, France, Italy, and Spain with universal healthcare coverage and well-structured rehabilitation systems that guarantee availability of treatment options. It is home to leading neurotoxin manufacturers, including Ipsen and Merz Therapeutics in France and Germany respectively, and provides platforms for extensive clinical and real-world evidence studies of various companies. National guidelines issued by organizations such as NICE recommend the use of botulinum toxin injection for focal spasticity following stroke and cerebral palsy. The Medical Device Regulation by European Union increased requirements for evidence for intrathecal pumps; however, established companies with clinical records have been maintaining steady sales in hospitals.

Germany is leading the market owing to abundance of neurology and rehabilitation clinics, high insurance coverage, and introduction of ultrasound-guided injection procedure. There is potential for growth in France because of centers specializing in multiple sclerosis and networks in physical and rehabilitation medicine. The UK has been extending community programs for spasticity management in order to reduce number of hospital visits, while Italy and Spain have growing populations with higher survival rates following strokes. Label extension for pediatric patients, as exemplified by Merz Therapeutics' EMA application for Xeomin to treat children aged 2 to 17 years old, will broaden the patient pool; however, price controls and generics will hinder revenue growth of oral agents.

Asia-Pacific Spasticity Drugs Market Insights

Asia-Pacific is currently witnessing the highest growth rate in the Spasticity Drugs Market, anticipated to record a CAGR of around 9.36% during the forecast period from 2026 to 2035, due to a large and aging population, rising stroke incidence, and rapid expansion of neurology and rehabilitation infrastructure. China is the largest market in the region, driven by the world’s highest stroke burden, growing hospital capacity, and increasing approvals of imported and domestic botulinum toxin products. Rising healthcare spending, wider insurance coverage under national reimbursement lists, and growing awareness among physicians about spasticity management after stroke and spinal cord injury are expanding treatment rates across urban and tier-two cities.

Japan still holds value due to its super aged population, presence of universal health insurance coverage, and widespread use of botulinum toxin treatment for post stroke limb spasticity. India emerges as an important growth contributor because of its large number of children affected by cerebral palsy, availability of cheap generic forms of baclofen and tizanidine, and the growing number of private rehabilitation centers. South Korea is able to take advantage of the presence of neurotoxin manufacturers such as Hugel and Daewoong Pharmaceutical that make products approved for post stroke spasticity within the country. Australia still invests in clinical studies, which include research on cannabinoids-based compounds for cerebral palsy treatment.

MEA & Latin America Spasticity Drugs Market Insights

The Middle East & Africa region represents a smaller but strategically important share of the Spasticity Drugs Market, led by Gulf Cooperation Council states such as Saudi Arabia and the UAE, which are investing heavily in specialized neurology hospitals and rehabilitation centers. Rising rates of road traffic injuries, stroke, and multiple sclerosis in the Gulf region are increasing demand for both oral drugs and botulinum toxin injections. Government health transformation programs and the presence of international hospital operators are improving access to advanced therapies. South Africa anchors demand across the wider African continent through its private healthcare sector, although limited specialist availability and budget constraints restrict adoption in many other countries.

There is consistent growth in Latin America, driven by Brazil, because of the country’s high population, excellent health care facilities and increasing number of rehab centers, even those dedicated to stroke and cerebral palsy patients. The increasing cases of stroke and brain injury along with the increased awareness about spasticity therapy have fueled the demand for botulinum toxins among hospitals of Brazil and Argentina. Private facilities of Mexico and Colombia are increasing access to their injectable medications and intrathecal pumps. However, budget constraints faced by public health care facilities and the dependency on cheaper generic oral medications hamper the growth of expensive products.

Market Dynamics:

Growth Drivers: Rising Neurological Disease Burden and Targeted Therapies

Growth in the Spasticity Drugs Market is primarily attributed to the rising global burden of neurological disorders, with an estimated 12 million people worldwide living with spasticity. Stroke remains a leading cause of long-term disability, and a significant share of survivors develop upper or lower limb spasticity within the first year. At the same time, more than 2.8 million people live with multiple sclerosis, and spastic cerebral palsy continues to affect a large pediatric population. Aging populations, better survival after stroke and spinal cord injury, and improved diagnosis are steadily expanding the number of patients who need long-term drug therapy to maintain mobility and independence.

Increasing reliance on neurotoxins in treatment options is driving growth in the market due to the efficacy of botulinum toxin injections and intrathecal baclofen in providing excellent symptoms control with less side effects compared to orally administered drugs. The use of guidance from ultrasound and electrical stimulation in enhancing injection accuracy has increased the willingness of physicians to use neurotoxin therapy in their routine treatment process. There has been an increase in adherence rates in patients due to patient friendly formulations such as baclofen oral suspension and granules.

Restraints: Side Effects, High Treatment Costs, and Generic Pricing Pressure

The side effects of systemic spasticity medicines have been acting as a barrier for the growth of the market. Baclofen, tizanidine, diazepam, and dantrolene that are orally administered have several side effects such as sleepiness, dizziness, weakness, and fatigue which may hamper compliance and may limit the dosing amount. Dantrolene causes liver toxicity while sudden withdrawal of intrathecal baclofen may pose certain problems. The Botulinum toxin injection may lead to weakness of muscles around the site of administration while in some cases patients do not respond with repeated cycles. Such safety issues compel doctors to administer the medicines in small amounts.

High treatment costs are another limiting factor, particularly for branded neurotoxins and intrathecal pump therapy, which require specialist administration, imaging guidance, and surgical implantation. In many low- and middle-income countries, limited insurance coverage and a shortage of trained physiatrists restrict access to these advanced options. Meanwhile, most oral spasticity drugs are available as low-cost generics, and intense price competition among manufacturers in India, China, and the United States keeps revenue growth modest for this large segment. Complex regulatory requirements for new formulations and devices, together with long approval timelines in markets such as Japan and the European Union, further slow the introduction of innovative products.

Opportunities: Pediatric Expansion, Novel Therapies, and Emerging Markets

Focus on pediatric spasticity provides an excellent chance for manufacturers to expand. Kids with cerebral palsy need chronic treatment and have few choices compared to adults, which allows extending indications of neurotoxins from age two to 17 as well as production of special liquid and granular formulations for children. Gene treatments for hereditary spastic paraplegia, cannabinoid candidates, and novel drugs that reduce muscle tone without causing sedation are other possible areas for developing treatments. Drug producers who combine medication with use of digital solutions for patients monitoring and rehabilitation programs will be able to differentiate their products and establish strong relationships with specialists.

At the same time, a quick formation of medical infrastructure in the Asia-Pacific, Latin American and Middle Eastern countries gives a chance to conquer a new growth market. The increase in the number of strokes, more extensive insurance coverage, as well as investments in neurology and rehabilitation centers, is increasing the need for oral generics and premium injectables in these regions. Manufacturers of neurotoxins in South Korea and China are growing exports while multinational companies establish distribution partners to penetrate new markets. Courses for training of physiatrists and neurologists in the technique of ultrasound-guided injection and tiered pricing strategy can help to gain more shares in these rapidly growing countries where spasticity treatment is poorly developed.

Recent Developments:

• 2026, Merz Therapeutics submitted an application to the European Medicines Agency to extend XEOMIN (incobotulinumtoxinA) to upper and lower limb spasticity in children and adolescents aged 2–17 years.

• 2025, BlackfinBio received FDA clearance of its IND application for BFB-101, an AAV gene therapy for hereditary spastic paraplegia type 47 (SPG47), enabling a Phase I/II study.

• 2024, Neurotech International received HREC and TGA approval to begin a Phase I/II clinical trial of NTI164 for treating spasticity in children with cerebral palsy in Australia.

Spasticity Drugs Market Key Players:

• AbbVie Inc. (Allergan)

• Ipsen S.A.

• Merz Therapeutics GmbH

• Medtronic plc

• Jazz Pharmaceuticals plc

• Teva Pharmaceutical Industries Ltd.

• Novartis AG

• Sun Pharmaceutical Industries Ltd.

• Amneal Pharmaceuticals, Inc.

• Saol Therapeutics Inc.

• Piramal Pharma Limited

• Azurity Pharmaceuticals, Inc.

• Bausch Health Companies Inc.

• Viatris Inc.

• Zydus Lifesciences Ltd.

• Lupin Limited

• Dr. Reddy’s Laboratories Ltd.

• Aurobindo Pharma Limited

• Hugel, Inc.

• Daewoong Pharmaceutical Co., Ltd.

Spasticity Drugs Market Report Scope: